

Form PTO-1449 (modified)

Atty. Docket No.
UTSC:594USD1/MBWSerial No.
09/974,753

List of Patents and Publications for Applicant's

Applicant
Alan J. SchroitCOPY OF PAPERS
ORIGINALLY FILED

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
October 9, 2001Group:
1642U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
W	A1	4,196,265	4/1/80	Koprowski <i>et al.</i>	435	70.21	8/11/78
W	A2	4,916,118	4/10/90	Fidler <i>et al.</i>	514	16	8/12/87
W	A3	4,916,448	4/10/90	Thor	340	970	2/26/88
W	A4	4,994,440	2/19/91	Creaven	514	8	2/13/89
W	A5	6,312,694 B1	11/6/01	Thorpe <i>et al.</i>	424	178.1	7/12/99

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
W	B1	JP 3197865	8/29/81	Japan			Abstract only

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
W	C1	"New cancer metastasis inhibitory compsn. for both humans and animals - comprises peptide cpds. having cell adhesive activity and lipid(s) having 14-24C fatty acid residue, sphingoglycolipid and cholesterol residues," abstract of JP08225457, <i>Derwent Publications Ltd.</i> , #AN 96-450927, 1996
W	C2	"Remington's Pharmaceutical Sciences" 15 Edition, pages 1035-1038 and 1570 and 1580.
W	C3	Allen and Choun, "Large unilamellar liposomes with low uptake into the reticuloendothelial system," <i>FEBS Lett.</i> , 223:42-46, 1987.
W	C4	Alving, "Antibodies to liposomes, phospholipids and phosphate esters," <i>Chem. Phys. Lipids</i> , 40:303-314, 1986.
W	C5	Asherson and Cervera, "Antiphospholipid Syndrome," <i>J. Invest. Dermatol.</i> , 100(1):21S-27S, 1993.
W	C6	Balasubramanian and Schroit, "Characterization of Phosphatidylserine-dependent β_2 -Glycoprotein I Macrophage Interactions," <i>J. Biol. Chem.</i> , 273(44), pgs. 29272-29277, 1998.

25123897.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



TECH CENTER 1600/2900

COPY OF PAPERS
ORIGINALLY FILED

Form PTO-1449 (modified)

Atty. Docket No.
UTSC:594USD1/MPWSerial No.
09/974,753COPY OF PAPERS
ORIGINALLY FILED

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
October 9, 2001Group:
1642U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
RECEIVED MAR 12 2002 TECH CENTER 1600/2900	C7	Baldwin <i>et al.</i> , "Surface exposure of phosphatidylserine is associated with the swelling and osmotically-induced fusion of human erythrocytes in the presence of Ca ²⁺ ," <i>Biochim. Biophys. Acta</i> , 1028:14-20, 1990.
	C8	Balet <i>et al.</i> , "1-Palmitoyl-2-thiopalmitoyl phosphatidylcholine, a highly specific chromogenic substrate of phospholipase A ₂ ," <i>Biochem. Biophys. Res. Commun.</i> , 150:561-567, 1988.
	C9	Banerji and Alving, "Antibodies to liposomal phosphatidylserine and phosphatidic acid," <i>Biochem. Cell. Biol.</i> , 68:96-101, 1990.
	C10	Bate <i>et al.</i> , "Phospholipids coupled to a carrier induce IgG antibody that blocks tumour necrosis factor induction by toxic malaria antigens," <i>Immunol.</i> , 79:138-145, 1993.
	C11	Becker <i>et al.</i> , "Antiphospholipid syndrome associated with immunotherapy for patients with melanoma," <i>Cancer</i> , 73:1621-1624, 1994.
	C12	Bennett <i>et al.</i> , "Binding and phagocytosis of apoptotic vascular smooth muscle cells is mediated in part by exposure of phosphatidylserine," <i>Circ. Res.</i> , 77:1136-1142, 1995.
	C13	Bervers <i>et al.</i> , "Changes in membrane phospholipid distribution during platelet activation," <i>Biochim. Biophys. Acta</i> , 736:57-66, 1983.
	C14	Bervers <i>et al.</i> , "Defective Ca ²⁺ -induced microvesiculation and deficient expression of procoagulant activity in erythrocytes from a patient with a bleeding disorder: a study of the red blood cells of scott syndrome," <i>Blood</i> , 79:380-388, 1992.
	C15	Bervers <i>et al.</i> , "Generation of Prothrombin-converting activity and the exposure of phosphatidylserine at the outer surface of platelets," <i>Eur. J. Biochem.</i> , 122:429-436, 1982.
	C16	Bruckheimer and Schroit, "Membrane phospholipid asymmetry: host response to the externalization of phosphatidylserine," <i>J. Leukocyte Biol.</i> , 59:784-788, 1996.
	C17	Brunner and Richards, "Analysis of membranes photolabeled with lipid analogues," <i>J. Biol. Chem.</i> , 255:3319-3329, 1980.
	C18	Comfurius <i>et al.</i> , "Enzymatic synthesis of phosphatidylserine on small scale by use of a one-phase system," <i>J. Lipid Res.</i> , 31:1719-1721, 1990.
	C19	Connor <i>et al.</i> , "Differentiation-dependent expression of phosphatidylserine in mammalian plasma membranes: quantitative assessment of outer-leaflet lipid by prothrombinase complex formation," <i>Proc. Natl. Acad. Sci. USA</i> , 86:3184, 1989.

25123897.1

EXAMINER:

Gary Bluth

DATE CONSIDERED:

3/19/03

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

COPY OF PAPERS
ORIGINALLY FILED

Form PTO-1449 (modified)

Atty. Docket No.
UTSC:594USD1/MBWSerial No.
09/974,753COPY OF PAPERS
ORIGINALLY FILED

List of Patents and Publications for Applicant's

Applicant
Alan J. Schroit

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
October 9, 2001Group:
1642U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
W	C20	Connor <i>et al.</i> , "Exposure of phosphatidylserine in the outer leaflet of human red blood cell." <i>Biol. Chem.</i> , 269:2399-2404, 1994.
W	C21	Couvreux <i>et al.</i> , "Nanocapsules: a new type of lysosomotropic carrier," <i>FEBS Lett.</i> , 84:323-326, 1977.
W	C22	Couvreux, "Polyalkylcyanoacrylates as colloidal drug carriers," <i>Crit. Rev. Ther. Drug Carrier Syst.</i> , 5:1-20, 1988.
W	C23	Creaven <i>et al.</i> , "Initial Clinical Trial of Muramyl Tripeptide Derivative (MTP-PE) Encapsulated in Liposomes: an Interim Report," <i>UCLA Symp. Mol. Cell. Biol.</i> , New Ser 89: 297-303, 1989, Abstract Only.
W	C24	Devaux and Zachowski, "Maintenance and consequences of membrane phospholipid asymmetry," <i>Chem. Phys. Lipids</i> , 73:107, 1994.
W	C25	Devaux, "Static and dynamic lipid asymmetry in cell membranes," <i>Biochemistry</i> , 30:1163-1173, 1991.
W	C26	Diaz <i>et al.</i> , "Generation of phenotypically aged phosphatidylserine-expressing erythrocytes by dialauroylphosphatidylcholine-induced vesiculation," <i>Blood</i> , 87:2956-2961, 1996.
W	C27	Diaz <i>et al.</i> , "Synthesis of disulfide-containing phospholipid analogs for the preparation of head group-specific lipid antigens: generation of phosphatidylserine antibodies," <i>Bioconjugate Chem.</i> , 9:250-254, 1998.
W	C28	Etemadi, "Membrane asymmetry, a survey and critical appraisal of the methodology, II. methods for assessing the unequal distribution of lipids," <i>Biochim. Biophys. Acta</i> , 604:423-475, 1980.
W	C29	Fadok <i>et al.</i> , "Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages," <i>J. Immunol.</i> , 148:2207-2216, 1992.
W	C30	Gabizon and Papahadjopoulos, "Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors," <i>Proc. Natl. Acad. Sci. USA</i> , 85:6949-6953, 1988.
W	C31	Gaffet <i>et al.</i> , "Phosphatidylserine exposure on the platelet plasma membrane during A23187-induced activation is independent of cytoskeleton reorganization," <i>Eur. J. Cell Biol.</i> , 67:336-345, 1995.

25123897.1

EXAMINER:

DATE CONSIDERED:

3/14/03

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



TECH CENTER 1600/2900

RECEIVED
MAR 12 2002

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSC:594USD1/MBW

09/974,753

COPY OF PAPERS
ORIGINALLY FILED

List of Patents and Publications for Applicant's

Applicant

Alan J. Schroit

INFORMATION DISCLOSURE STATEMENT

Filing Date:

October 9, 2001

Group:

1642

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

COPY OF PAPERS
ORIGINALLY FILED

Exam. Init.	Ref. Des.	Citation
W	C32	Galli <i>et al.</i> , "Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor," <i>Lancet</i> , 335:1544-1547, 1990.
W	C33	Gefter <i>et al.</i> , "Simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells," <i>Somat. Cell Genet.</i> , 3:231-236, 1977.
W	C34	Geldwerth <i>et al.</i> , "Transbilayer mobility and distribution of red cell phospholipids during storage," <i>J. Clin. Invest.</i> , 92:308-314, 1993.
W	C35	Ghosh and Bachhawat, "Targeting of Liposomes to Hepatocytes," <i>Targeted Diagn. Ther.</i> , 4:87-103, 1991.
W	C36	Goding, "Monoclonal Antibodies: Principles and Practice," pp. 60-74. 2nd Edition, Academic Press, Orlando, FL, 1986.
W	C37	Gordesky <i>et al.</i> , "The reaction of chemical probes with the erythrocyte membrane," <i>J. Membr. Biol.</i> , 20:111-132, 1975.
W	C38	Grassetti and Murray, "Determination of sulfhydryl groups with 2,2'- or 4,4'-dithiodipyridine," <i>Arch. Biochem. Biophys.</i> , 119:41-49, 1967.
.	C39	Gupta <i>et al.</i> , "Adjuvants for human vaccines—current status, problems and future prospects," <i>Vaccine</i> , 13(14):1263-1276, 1995
	C40	Henry-Michelland <i>et al.</i> , "Attachment of antibiotics to nanoparticles: preparation, drug release, and antimicrobial activity in vitro," <i>Int. J. Pharm.</i> , 35:121-127, 1987.
W	C41	Herrmann and Devaux, "Alteration of the aminophospholipid translocase activity during in vivo and artificial aging of human erythrocytes," <i>Biochim. Biophys. Acta</i> , 1027:41-46, 1990.
W	C42	Herstoff and Bogaars, "Cutaneous lupus erythematosus associated with melanoma and BCG vaccine therapy," <i>Arch. Dermatol.</i> , 115(7):856-859, 1979.
	C43	Janeway <i>et al.</i> , <i>Immunobiology</i> , Garland Publishing, page 1:32, 1994.
W	C44	Jue <i>et al.</i> , "Addition of sulfhydryl groups to <i>Escherichia coli</i> ribosomes by protein modification with 2-iminothiolane (methyl 4-mercaptobutyrimide)," <i>Biochemistry</i> , 17:5399-5405, 1978.
W	C45	Katsuragawa <i>et al.</i> , "Monoclonal antiphosphatidylserine antibody reactivity against human first-trimester placental trophoblasts," <i>Am. J. Obstet. Gynecol.</i> , 172:1592-1597, 1995.


25123897.1

EXAMINER:

DATE CONSIDERED:

3/19/03

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



TECH CENTER 1600/2900

Form PTO-1449 (modified)

Atty. Docket No.
UTSC:594USD1/MBWSerial No.
09/974,753COPY OF PAPERS
ORIGINALLY FILED

List of Patents and Publications for Applicant's

Applicant
Alan J. Schroit

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
October 9, 2001Group:
1642U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

COPY OF PAPERS
ORIGINALLY FILED

Exam. Init.	Ref. Des.	Citation
aw	C46	Killion and Baker, "Autoreactive factors identify tumor-host heterogeneity and responsiveness to immunotherapy," <i>Cancer Immunol Immunother.</i> , 12:111-117, 1982.
aw	C47	Kohler and Milstein, "Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion," <i>Eur. J. Immunol.</i> , 6:511-519, 1976.
aw	C48	Kuypers <i>et al.</i> , "Detection of altered membrane phospholipid asymmetry in subpopulations of human red blood cells using fluorescently labeled annexin V," <i>Blood</i> , 87:1179-1187, 1996.
aw	C49	Mackworth-Young, "Antiphospholipid antibodies: more than just a disease marker?," <i>Immunol. Today</i> , 11(2):60-65, 1990.
aw	C50	Maneta-Peyret <i>et al.</i> , "Demonstration of high specificity antibodies against phosphatidylserine," <i>J. Immun. Met.</i> , 108:123-127, 1988.
aw	C51	Maneta-Peyret <i>et al.</i> , "Demonstration that anti-phospholipid auto-antibodies react with both anionic d zwitterionic phospholipids," <i>Immunol. Lett.</i> , 35:141-146, 1993.
aw	C52	Maneta-Peyret <i>et al.</i> , "Specific immunocytochemical visualization of phyosphatidylserine," <i>J. Immunol. Meth.</i> , 122:155-159, 1989.
aw	C53	McNeil <i>et al.</i> , "Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β_2 -glycoprotein I (apolipoprotein H)," <i>Proc. Natl. Acad. Sci. USA</i> , 87:4120-4124, 1990.
aw	C54	Menon, "Flippases," <i>Trends Cell Biol.</i> , 5:355, 1995.
aw	C55	Mizushima and Igarashi, "Studies on polypeptide drug delivery systems: tissue distribution of immunoglobulin G conjugated with lecithin," <i>J. of Controlled Release</i> , 17:99-104, 1991.
aw	C56	Moestrup <i>et al.</i> , " β_2 -Glycoprotein-I (Apolipoprotein H) and β_2 -Glycoprotein-I-Phospholipid Complex Harbor a Recognition Site for the Endocytic Receptor Megalin," <i>J. Clin. Invest.</i> , 102(5), pgs. 902-909, 1998
aw	C57	Naldi <i>et al.</i> , "Antiphospholipid antibodies and melanoma: a link?," <i>Dermatology</i> , 184(2):156, 1992.
aw	C58	Nelson, "Autoantibodies in cancer patients," <i>Pathology</i> , 9(2):155-160, 1977.

25123897.1


EXAMINER:

DATE CONSIDERED:

3/9/03

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



TECH CENTER 1600/2900

RECEIVED
MAR 12 2002

Form PTO-1449 (modified)

Atty. Docket No.
UTSC:594USD1/MBWSerial No.
09/974,753COPY OF PAPERS
ORIGINALLY FILED

List of Patents and Publications for Applicant's

Applicant
Alan J. Schroit

INFORMATION DISCLOSURE STATEMENT

Filing Date:
October 9, 2001Group:
1642

(Use several sheets if necessary)

U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
W	C59	OoSting <i>et al.</i> , "Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein c, or protein s: an explanation for their pathogenic mechanism," <i>Blood</i> , 81:2618-2625, 1993.
W	C60	Pierotti and Colnaghi, "Natural antibodies directed against murine lymphosarcoma cells," <i>J. Natl. Cancer Inst.</i> , 55(4):945-949, 1975.
W	C61	Poltz and Kostner, "The binding of β_2 -glycoprotein-I to human serum lipoproteins," <i>FEBS Lett.</i> , 102:183-186, 1979.
W	C62	Rauch and Janoff, "Phospholipid in the hexagonal II phase is immunogenic: evidence for immunorecognition of nonbilayer lipid phases <i>in vivo</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 87:4112-4114, 1990.
W	C63	Rauch <i>et al.</i> , "Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems," <i>J. Biol. Chem.</i> , 262:9672-9677, 1986.
W	C64	Regen, "Polymerized-depolymerized vesicles. A reversible phosphatidylcholine-based membrane," <i>J. Am. Chem. Soc.</i> , 105:6354-6355, 1983.
W	C65	Riddles <i>et al.</i> , "Reassessment of ellman's reagent," <i>Meth. Enzymol.</i> , 91:49-60, 1983.
W	C66	Rosenberg and Rogentine, "Natural human antibodies to "hidden" membrane components," <i>Nature</i> , 239:203, 1972.
W	C67	Rosing <i>et al.</i> , "The role of activated human platelets in prothrombin and factor x activation," <i>Blood</i> , 65:319-322, 1985.
W	C68	Rosing <i>et al.</i> , "The role of phospholipids and factor V _a in the prothrombinase complex," <i>J. Biol. Chem.</i> , 255:274-283, 1980.
W	C69	Rote <i>et al.</i> , "Expression of phosphatidylserine-dependent antigens on the surface of differentiating BeWo human choriocarcinoma cells," <i>Am. J. Rep. Immunol.</i> , 33:114-121, 1995.
W	C70	Rote <i>et al.</i> , "Immunologic detection of phosphatidylserine externalization during thrombin-induced platelet activation," <i>Clin. Immunol. Immunopathol.</i> , 66:193-200, 1993.
W	C71	Roubey, "Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies," <i>Blood</i> , 84:2854-2867, 1994.

25123897.1

EXAMINER:

DATE CONSIDERED:

3/19/03

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

TECH CENTER 1600/2900

COPY OF PAPERS
ORIGINALLY FILED

Form PTO-1449 (modified)

Atty. Docket No.

UTSC:594USD1/MBW

Serial No.

09/974,753

COPY OF PAPERS
ORIGINALLY FILED

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

October 9, 2001

Group:

1642

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>aw</i>	C72	Sambrano and Steinberg, "Recognition of oxidatively damaged and apoptotic cells by an oxidized low density lipoprotein receptor on mouse peritoneal macrophages: role of membrane phosphatidylserine," <i>Proc. Natl. Acad. Sci. USA</i> , 92:1396-1400, 1995.
<i>aw</i>	C73	Samuel <i>et al.</i> , "Polymerized-depolymerized vesicles. Reversible thiol-disulfide-based phosphatidylcholine membrane," <i>J. Am. Chem. Soc.</i> , 107:42-47, 1985.
<i>aw</i>	C74	Schick <i>et al.</i> , "Location of phosphatidylethanolamine and phosphatidylserine in the human platelet plasma membrane," <i>J. Clin. Invest.</i> , 57:1221-1226, 1976.
<i>aw</i>	C75	Schousboe, "Purification, characterization and identification of an agglutinin in human serum," <i>Biochim. Biophys. Acta</i> , 579:396-408, 1979.
<i>aw</i>	C76	Schroit and Madsen, "Synthesis and properties of radioiodinated phospholipid analogues that spontaneously undergo vesicle-vesicle and vesicle-cell transfer," <i>Biochemistry</i> , 22:3617-3623, 1983.
<i>aw</i>	C77	Schroit and Zwaal, "Transbilayer movement of phospholipids in red cell and platelet membranes," <i>Biochim. Biophys. Acta</i> , 1071:313-329, 1991.
<i>aw</i>	C78	Sims <i>et al.</i> , "Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane," <i>J. Biol. Chem.</i> , 264:17049-17057, 1989.
<i>aw</i>	C79	Tait and Gibson, "Measurement of membrane phospholipid asymmetry in normal and sickle-cell erythrocytes by means of annexin V binding," <i>J. Lab. Clin. Med.</i> , 123:741-748, 1994.
<i>aw</i>	C80	Tamamura <i>et al.</i> , "The immunological relations between acidic phospholipids and their antibodies," <i>Jpn. J. Exp. Med.</i> , 41:31-38, 1971.
	C81	Tannock <i>et al.</i> , <i>The Basic Science of Oncology</i> , 2 nd Edition, page 247, 1 st column, 1992.
<i>aw</i>	C82	Thiagarajan and Tait, "Binding of annexin V/Placental anticoagulant protein I to platelets," <i>J. Biol. Chem.</i> , 265:17420-17423, 1990.
<i>aw</i>	C83	Umeda, "Effective production of monoclonal antibodies against phosphatidylserine: stereospecific recognition of phosphatidylserine by monoclonal antibody," <i>Immunol.</i> , 143:2273-2279, 1989.
<i>aw</i>	C84	Utsugi <i>et al.</i> , "Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes," <i>Cancer Res.</i> , 51(11):3062-3066, 1991.

25123897.1


EXAMINER:

DATE CONSIDERED:

3/19/03

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



TECH CENTER 1600/2900

COPY OF PAPERS
ORIGINALLY FILED

Form PTO-1449 (modified)

Atty. Docket No.
UTSC:594USD1/MBWSerial No.
09/974,753COPY OF PAPERS
ORIGINALLY FILED

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
October 9, 2001Group:
1642U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1COPY OF PAPERS
ORIGINALLY FILED

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
W	C85	Van Dieijen <i>et al.</i> , "The role of phospholipid and factor VIII _a in the activation of bovine factor x," <i>J. Biol. Chem.</i> , 256:3433-3442, 1981.
W	C86	Verhoven <i>et al.</i> , "Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic t lymphocytes," <i>J. Exp. Med.</i> , 182:1597-1601, 1995.
W	C87	Verkleij <i>et al.</i> , "The asymmetric distribution of phospholipids in the human red cell membrane, a combined study using phospholipases and freeze-etch electron microscopy," <i>Biochim. Biophys. Acta</i> , 323(2):178-193, 1973.
W	C88	Vermes <i>et al.</i> , "A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin v," <i>J. Immunol. Meth.</i> , 184:39-51, 1995.
W	C89	Wurm, "β ₂ -glycoprotein-I (apolipoprotein h) interactions with phospholipid vesicles," <i>Int. J. Biochem.</i> , 16:511-515, 1984.
W	C90	Zwaal and Schroit, "Pathophysiologic implications of membrane phospholipid asymmetry in blood cells," <i>Blood</i> , 89:1121-1132, 1997.
W	C91	Zwaal <i>et al.</i> , "Organization of phospholipids in human red cell membranes as detected by the action of various purified phospholipases," <i>Biochim. Biophys. Acta</i> , 406(1):83-96, 1975.

25123897.1

EXAMINER:

DATE CONSIDERED:

3/19/03

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



TECH CENTER 1600/2900